Literature DB >> 18938111

Hyperexpression of NOD2 in intestinal mast cells of Crohn's disease patients: preferential expression of inflammatory cell-recruiting molecules via NOD2 in mast cells.

Shigeru Okumura1, Keisuke Yuki, Ryota Kobayashi, Shinichi Okamura, Kazumitsu Ohmori, Hirohisa Saito, Chisei Ra, Yoshimichi Okayama.   

Abstract

NOD2, an intracellular sensor of bacteria-derived muramyl dipeptide (MDP) has been implicated as a key player in intestinal immune health and disease. Mast cells (MCs) have been reported to be increased in the gut of patients with inflammatory bowel disease. However, NOD2 expression and its role in human primary MCs are unknown. The number of NOD2(+) intestinal MCs was significantly increased in the Crohn's disease (CD) specimens compared to Ulcerative colitis (UC) specimens and controls. IFN-gamma upregulated NOD2 expression in MCs. CXCL10 and urokinase-type plasminogen activator (uPA) upregulation was specific to MCs activated by MDP compared to MCs activated by LPS and IgE/anti-IgE. MDP-induced upregulation of ICAM-1, VCAM-1, and uPA was specific to MCs compared to mononuclear cells. The number of CXCL10(+)NOD2(+) intestinal MCs was significantly increased in the CD patients. Our results suggest that NOD2(+) MCs have specific pathogenic roles that involve the recruitment of inflammatory cells in CD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18938111     DOI: 10.1016/j.clim.2008.08.027

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  13 in total

1.  Schistosoma japonicum ova maintains epithelial barrier function during experimental colitis.

Authors:  Chen-Mei Xia; Yuan Zhao; Li Jiang; Jie Jiang; Shun-Cai Zhang
Journal:  World J Gastroenterol       Date:  2011-11-21       Impact factor: 5.742

2.  Tumor necrosis factor alpha modulates the dynamics of the plasminogen-mediated early interaction between Bifidobacterium animalis subsp. lactis and human enterocytes.

Authors:  Manuela Centanni; Simone Bergmann; Silvia Turroni; Sven Hammerschmidt; Gursharan Singh Chhatwal; Patrizia Brigidi; Marco Candela
Journal:  Appl Environ Microbiol       Date:  2012-01-27       Impact factor: 4.792

3.  Infection of mast cells with live streptococci causes a toll-like receptor 2- and cell-cell contact-dependent cytokine and chemokine response.

Authors:  Elin Rönnberg; Bengt Guss; Gunnar Pejler
Journal:  Infect Immun       Date:  2009-11-23       Impact factor: 3.441

Review 4.  The multifaceted mast cell in inflammatory bowel disease.

Authors:  Matthew J Hamilton; Sandra M Frei; Richard L Stevens
Journal:  Inflamm Bowel Dis       Date:  2014-12       Impact factor: 5.325

Review 5.  Regulation of type 2 immunity to helminths by mast cells.

Authors:  Matthew R Hepworth; Marcus Maurer; Susanne Hartmann
Journal:  Gut Microbes       Date:  2012-08-15

Review 6.  Intestinal bacteria and the regulation of immune cell homeostasis.

Authors:  David A Hill; David Artis
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

Review 7.  The role of TLRs, NLRs, and RLRs in mucosal innate immunity and homeostasis.

Authors:  E C Lavelle; C Murphy; L A J O'Neill; E M Creagh
Journal:  Mucosal Immunol       Date:  2009-11-04       Impact factor: 7.313

8.  IL-1α and IL-1β promote NOD2-induced immune responses by enhancing MAPK signaling.

Authors:  Sushan Li; Ping Deng; Manzhi Wang; Xueting Liu; Manli Jiang; Binyuan Jiang; Li Yang; Jinyue Hu
Journal:  Lab Invest       Date:  2019-04-24       Impact factor: 5.662

9.  IL-6 effector function of group 2 innate lymphoid cells (ILC2) is NOD2 dependent.

Authors:  Clare S Hardman; Yi-Ling Chen; Maryam Salimi; Janina Nahler; Daniele Corridoni; Marta Jagielowicz; Chathuranga L Fonseka; David Johnson; Emmanouela Repapi; David J Cousins; Jillian L Barlow; Andrew N J McKenzie; Alison Simmons; Graham Ogg
Journal:  Sci Immunol       Date:  2021-05-21

Review 10.  Nod2: The intestinal gate keeper.

Authors:  Ziad Al Nabhani; Gilles Dietrich; Jean-Pierre Hugot; Frederick Barreau
Journal:  PLoS Pathog       Date:  2017-03-02       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.